REG - e-Therapeutics plc - Director Dealing and Issue of Equity

E-TherapeuticsAnnouncement

09/01/2024 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240109:nRSI1398Za&default-theme=true

RNS Number : 1398Z  e-Therapeutics plc  09 January 2024

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Director Dealing and Issue of Equity

 

 

London, UK, 9 January 2024 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
company integrating computational power and biological data to discover
life-transforming RNAi medicines, today announces that on 9 January 2024,
Professor Trevor Jones (Non-Executive Chairman of the Company) subscribed for
a total of 91,325 new ordinary shares of 0.1p each in the Company (the "New
Ordinary Shares") at a price of 8.28 pence per share. The subscription monies
paid for the New Ordinary Shares represent 50% of Professor Jones'
Non-Executive Director fees net of tax paid during the period from 1 July 2023
to 31 December 2023 in accordance with the agreement entered into with
Professor Jones, previously announced on 5 October 2016, by which Professor
Jones agreed, with effect from 1 October 2016, to invest 50% of his annual
Non-Executive Director fees net of tax in new e-therapeutics' ordinary shares.
Such new shares are issued to Professor Jones on the first business day after
31 December and 30 June in each year. The subscription price to be paid is the
average of the closing mid-market price for the five business days prior to
the date of issue.

 

Application has been made to AIM for the admission of the New Ordinary Shares
to trading on AIM ("Admission") and Admission is expected to occur at 8:00
a.m. on or around 15 January 2024. The New Ordinary Shares will rank pari
passu in all respects with the Company's existing ordinary shares in issue.

 

Following Admission, Professor Jones will be interested in a total of
1,293,896 ordinary shares of 0.1p in the Company, representing approximately
0.22% of the Company's issued share capital.

 

Following Admission, the total number of ordinary shares in the Company with
voting rights in issue will be 583,935,487. This figure may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further details:

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Trevor Jones
 2   Reason for the notification
 a)  Position/status                                              Non-Executive Chairman
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         e-therapeutics plc
 b)  LEI                                                          21380049RHSSJXWKYT18
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence

     Identification code

                                                                  ISIN: GB00B2823H99
 b)  Nature of the transaction                                    Purchase of shares
 c)  Price(s) and volume(s)                                       91,325 ordinary shares at a price of 8.28 pence per share
 d)  Aggregated information                                       91,325 ordinary shares

     - Aggregated volume                                          8.28 pence per share

     - Price                                                      Aggregated value: £7,561.71

 e)  Date of the transaction                                      9 January 2024

 f)  Place of the transaction                                     Outside a trading venue

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                                                    Tel: +44 (0)20 4551 8888

 Timothy Bretherton,                                                                   www.etherapeutics.co.uk (http://www.etherapeutics.co.uk)
 CFO

      SP Angel Corporate Finance LLP                                                   Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines. The Company's
technology uses computation to capture and model human biology, identify novel
targets, and develop RNAi medicines against those targets that can be rapidly
progressed to the clinic.

 

ETX's proprietary HepNet™ platform enables the generation and analysis of
biological network models, providing a novel and mechanistic approach to drug
discovery. This approach explicitly considers the true complexity of biology
to make more reliable predictions from large complex data sets and ETX's
proprietary hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource.  The Company generates,
prioritises, and tests millions of hypotheses in silico to identify better
therapeutic targets with higher confidence.

 

GalOmic™, ETX's proprietary RNAi platform, enables targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by HepNet™. The focus on hepatocytes
offers the opportunity to tackle a wide variety of diseases.  The liver is a
highly metabolically active organ which performs a key role in many biological
processes and vital functions crucial for human health. ETX's GalOmic™
constructs have demonstrated compelling in vivo performance in terms of depth
of gene silencing and duration of action.

 

The Company is progressing a pipeline of first-in-class RNAi candidates across
a variety of therapeutic areas with high unmet need, including preclinical
programs in cardiometabolic and metabolic diseases, haemophilia, and other
undisclosed indications. ETX has also partnered with biopharma companies such
as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational
network biology approach across a diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFIRLVIAIIS